One “late phase” breast cancer study, according to Dienstmann et al., showed an increased pathological complete response in the neoadjuvant setting when treating HER2-positive patients also harboring an amplification of TOP2A with anthracyclines38. The gene discussed is TOP2A; the disease is breast carcinoma.